

AMAG PHARMACEUTICALS INC.

Form 8-K

March 26, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **March 25, 2010**

AMAG PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-14732

(Commission File Number)

04-2742593

(IRS Employer Identification No.)

**100 Hayden Avenue
Lexington, Massachusetts**
(Address of principal executive offices)

02421
(Zip Code)

(617) 498-3300

(Registrant's telephone number, including area code)

Edgar Filing: AMAG PHARMACEUTICALS INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On March 25, 2010, AMAG Pharmaceuticals, Inc., or the Company, was served with a complaint, or the Complaint, naming the Company, its chief executive officer and its chief financial officer as defendants in a purported class action lawsuit, Silverstrand Investments v. AMAG Pharmaceuticals, Inc. et al (Case No. 10 Civ. 10470), filed in the United States District Court for the District of Massachusetts. The Complaint alleges violations by the Company and its chief executive officer and its chief financial officer of the Securities Act of 1933, as amended, in connection with the Company's January 2010 common stock offering.

The Company believes that the allegations are without merit and intends to vigorously defend against this action.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMAG PHARMACEUTICALS, INC.

By: */s/ Joseph L. Farmer*
Joseph L. Farmer
General Counsel and Senior Vice
President of Legal Affairs

Date: March 25, 2010